Author:
Lan Ying,Yang Nan,Wang Yirong,Yang Yan,Xu Min,He Qin
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pulmonary and Respiratory Medicine,General Medicine
Reference39 articles.
1. Chronic Obstructive Pulmonary Disease Group. Respiratory Diseases Branch of Chinese Medical Association Chronic Obstructive Pulmonary Disease Working Committee of the Respiratory Physician Branch of the Chinese Medical Doctor Association, Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis. 2021;44(3):170–204.
2. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
3. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2021. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed December 21, 2021.
5. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献